Back to Biology: New Insights on Inheritance in Myeloproliferative Disorders

Current Hematologic Malignancy Reports

Volumn 9, Issue 4, 2014, Pages 311-318

  Braunstein, Evan M ^a   Moliterno, Alison R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Familial myeloproliferative disorder; Hereditary erythrocytosis; Hereditary thrombocytosis

Indexed keywords

ALLELE; AUTOSOMAL DOMINANT INHERITANCE; CLONAL VARIATION; DISEASE COURSE; FAMILIAL CANCER; GAIN OF FUNCTION MUTATION; GENE MUTATION; GENETIC DISORDER; GENETIC PREDISPOSITION; GENETIC RISK; GENETICS; GERMLINE MUTATION; HEREDITARY ERYTHROCYTOSIS; HEREDITARY THROMBOCYTOSIS; HUMAN; INHERITANCE; MYELOPROLIFERATIVE DISORDER; PROTEIN FUNCTION; REVIEW; SOMATIC MUTATION; POLYCYTHEMIA;

HUMANS; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA;

EID: 84920268904     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-014-0232-3     Document Type: Review

References (52)

1. Skoda RC. Hereditary myeloproliferative disorders. Haematologica. 2010;95(1):6–8.
2. Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123(14):2220–8. Used targeting next-generation sequencing to search for mutations in a large cohort of MPD patients. Found that the overall mutation rate in MPD is low and correlated survival to number of somatic mutations.
3. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–90. Identified CALR as a frequently mutated gene in MPD.
4. Makishima H, Maciejewski JP. Pathogenesis and consequences of uniparental disomy in cancer. Clin Cancer Res. 2011;17(12):3913–23.
5. Kralovics R. Genetic complexity of myeloproliferative neoplasms. Leukemia. 2008;22(10):1841–8.
6. Landgren O, Goldin LR, Kristinsson SY, Helgadottir EA, Samuelsson J, Bjorkholm M. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden. Blood. 2008;112(6):2199–204.
7. Rumi E, Passamonti F, Della Porta MG, Elena C, Arcaini L, Vanelli L, et al. Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. J Clin Oncol. 2007;25(35):5630–5.
8. Olcaydu D, Rumi E, Harutyunyan A, Passamonti F, Pietra D, Pascutto C, et al. The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. Haematologica. 2011;96(3):367–74.
9. Bellanne-Chantelot C, Chaumarel I, Labopin M, Bellanger F, Barbu V, De Toma C, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood. 2006;108(1):346–52.
10. Malak S, Labopin M, Saint-Martin C, Bellanne-Chantelot C, Najman A, French Group of Familial Myeloproliferative Disorders. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications. Blood Cells Mol Dis. 2012;49(3–4):170–6.
11. Pietra D, Li S, Brisci A, Passamonti F, Rumi E, Theocharides A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood. 2008;111(3):1686–9.
12. Saint-Martin C, Leroy G, Delhommeau F, Panelatti G, Dupont S, James C, et al. Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood. 2009;114(8):1628–32.
13. Maffioli M, Genoni A, Caramazza D, Mora B, Bussini A, Merli M, et al. Looking for CALR mutations in familial myeloproliferative neoplasms. Leukemia. 2014;28(6):1357–60.
14. Lundberg P, Nienhold R, Ambrosetti A, Cervantes F, Perez-Encinas MM, Skoda RC. Somatic mutations in calreticulin can be found in pedigrees with familial predisposition to myeloproliferative neoplasms. Blood. 2014;123(17):2744–5.
15. Rumi E, Passamonti F, Pietra D, Della Porta MG, Arcaini L, Boggi S, et al. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer. 2006;107(9):2206–11.
16. Pardanani A, Lasho T, McClure R, Lacy M, Tefferi A. Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disorders. Blood. 2006;107(11):4572–3.
17. Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL, et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet. 2009;41(4):455–9.
18. Olcaydu D, Harutyunyan A, Jager R, Berg T, Gisslinger B, Pabinger I, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet. 2009;41(4):450–4.
19. Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet. 2009;41(4):446–9.
20. Gordeuk VR, Stockton DW, Prchal JT. Congenital polycythemias/erythrocytoses. Haematologica. 2005;90(1):109–16.
21. Teofili L, Larocca LM. Advances in understanding the pathogenesis of familial thrombocythaemia. Br J Haematol. 2011;152(6):701–12.
22. Prchal JT. Pathogenetic mechanisms of polycythemia vera and congenital polycythemic disorders. Semin Hematol. 2001;38(1 Suppl 2):10–20.
23. Rumi E. Familial chronic myeloproliferative disorders: the state of the art. Hematol Oncol. 2008;26(3):131–8.
24. Kralovics R, Prchal JT. Genetic heterogeneity of primary familial and congenital polycythemia. Am J Hematol. 2001;68(2):115–21.
25. Liu E, Jelinek J, Pastore YD, Guan Y, Prchal JF, Prchal JT. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood. 2003;101(8):3294–301.
26. Rives S, Pahl HL, Florensa L, Bellosillo B, Neusuess A, Estella J, et al. Molecular genetic analyses in familial and sporadic congenital primary erythrocytosis. Haematologica. 2007;92(5):674–7.
27. Ghilardi N, Wiestner A, Skoda RC. Thrombopoietin production is inhibited by a translational mechanism. Blood. 1998;92(11):4023–30.
28. Wiestner A, Schlemper RJ, van der Maas AP, Skoda RC. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat Genet. 1998;18(1):49–52.
29. Ding J, Komatsu H, Iida S, Yano H, Kusumoto S, Inagaki A, et al. The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-mpl protein due to strong amino acid polarity. Blood. 2009;114(15):3325–8.
30. El-Harith e-HA, Roesl C, Ballmaier M, Germeshausen M, Frye-Boukhriss H, von Neuhoff N, et al. Familial thrombocytosis caused by the novel germ-line mutation p.Pro106Leu in the MPL gene. Br J Haematol. 2009;144(2):185–94.
31. Moliterno AR, Williams DM, Gutierrez-Alamillo LI, Salvatori R, Ingersoll RG, Spivak JL. Mpl baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis. Proc Natl Acad Sci U S A. 2004;101(31):11444–7.
32. Rumi E, Harutyunyan AS, Casetti I, Pietra D, Nivarthi H, Moriggl R, et al. A novel germline JAK2 mutation in familial myeloproliferative neoplasms. Am J Hematol. 2014;89(1):117–8.
33. Mead AJ, Rugless MJ, Jacobsen SE, Schuh A. Germline JAK2 mutation in a family with hereditary thrombocytosis. N Engl J Med. 2012;366(10):967–9.
34. Marty C, Saint-Martin C, Pecquet C, Grosjean S, Saliba J, Mouton C, et al. Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. Blood. 2014;123(9):1372–83. Identified novel germline JAK2 mutations and showed that they are biologically less active than the V617F mutation.
35. Etheridge SL, Cosgrove ME, Sangkhae V, Corbo LM, Roh ME, Seeliger MA, et al. A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis. Blood. 2014;123(7):1059–68.
36. Mead AJ, Chowdhury O, Pecquet C, Dusa A, Woll P, Atkinson D, et al. Impact of isolated germline JAK2V617I mutation on human hematopoiesis. Blood. 2013;121(20):4156–65. Found that the V617I mutation induces cytokine hyperresponsiveness and may expand the bone marrow stem cell population.
37. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779–90.
38. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108(10):3472–6.
39. Teofili L, Giona F, Torti L, Cenci T, Ricerca BM, Rumi C, et al. Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis. Haematologica. 2010;95(1):65–70.
40. Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 2008;112(1):141–9.
41. Prchal JT. Polycythemia vera and other primary polycythemias. Curr Opin Hematol. 2005;12(2):112–6.
42. Liu K, Martini M, Rocca B, Amos CI, Teofili L, Giona F, et al. Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia. Haematologica. 2009;94(10):1368–74.
43. Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, et al. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol. 2007;25(9):1048–53.
44. Kralovics R, Teo SS, Li S, Theocharides A, Buser AS, Tichelli A, et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006;108(4):1377–80.
45. Schaub FX, Looser R, Li S, Hao-Shen H, Lehmann T, Tichelli A, et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood. 2010;115(10):2003–7.
46. Kralovics R, Stockton DW, Prchal JT. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood. 2003;102(10):3793–6.
47. Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014;506(7488):328–33.
48. Harutyunyan AS, Kralovics R. Role of germline genetic factors in MPN pathogenesis. Hematol Oncol Clin N Am. 2012;26(5):1037–51.
49. Skoda R, Prchal JT. Lessons from familial myeloproliferative disorders. Semin Hematol. 2005;42(4):266–73.
50. Higgs JR, Sadek I, Neumann PE, Ing VW, Renault NK, Berman JN, et al. Familial essential thrombocythemia with spontaneous megakaryocyte colony formation and acquired JAK2 mutations. Leukemia. 2008;22(8):1551–6.
51. Posthuma HL, Skoda RC, Jacob FA, van der Maas AP, Valk PJ, Posthuma EF. Hereditary thrombocytosis not as innocent as thought? Development into acute leukemia and myelofibrosis. Blood. 2010;116(17):3375–6.
52. Koboldt DC, Steinberg KM, Larson DE, Wilson RK, Mardis ER. The next-generation sequencing revolution and its impact on genomics. Cell. 2013;155(1):27–38.